cisplatin, nivolumab
Nivolumab ປະສົມປະສານກັບ cisplatin ແລະ gemcitabine ໄດ້ຮັບການອະນຸມັດໂດຍ USFDA ສໍາລັບມະເຮັງ urothelial ທີ່ບໍ່ແກ້ໄຂໄດ້ຫຼື metastatic.
March 2024: The Food and Drug Administration has granted approval for the use of nivolumab (Opdivo, Bristol-Myers Squibb Company) in conjunction with cisplatin and gemcitabine as the initial treatment for adult patients with unres..
ເປບໂບລິຊູມາບ, USFDA
Enfortumab vedotin-ejfv ກັບ pembrolizumab ໄດ້ຮັບການອະນຸມັດໂດຍ USFDA ສໍາລັບທ້ອງຖິ່ນທີ່ກ້າວຫນ້າທາງດ້ານຫຼື metastatic urothelial carcinoma
Feb 2024: The Food and Drug Administration has sped up the approval process for two drugs, enfortumab vedotin-ejfv (Padcev, Astellas Pharma) and pembrolizumab (Keytruda, Merck). These drugs are meant to treat people with locally ..
Bristol Myers Squibb, ກວດກາ-274, nivolumab, ອັດສະຈັນ, ມະເລັງ urothelial
Nivolumab ໄດ້ຮັບການອະນຸມັດຈາກ FDA ເພື່ອໃຊ້ເປັນການປິ່ນປົວເສີມສໍາລັບການເປັນມະເຮັງ urothelial
August 2021: Nivolumab (Opdivo, Bristol-Myers Squibb Co.) has been approved by the Food and Drug Administration for the adjuvant treatment of patients with urothelial carcinoma (UC) who are at high risk of recurrence following rad..
Astellas Pharma US, NCT03474107, Padcev, Trial EV-301
FDA ໄດ້ໃຫ້ການອະນຸມັດ vedotin-ejfv enfortumab ສໍາລັບການປິ່ນປົວຂອງ carcinoma urothelial ຂັ້ນສູງໃນທ້ອງຖິ່ນຫຼື metastatic ໃນທ້ອງຖິ່ນ.
August 2021: Enfortumab vedotin-ejfv (Padcev, Astellas Pharma US, Inc.), a Nectin-4-directed antibody and microtubule inhibitor combination, has been approved by the Food and Drug Administration for adult patients with locally adv..
ບໍລິສັດພູມຕ້ານທານ Inc, mUC, ການປິ່ນປົວດ້ວຍຢາເຄມີທີ່ບັນຈຸມີ platinum, programmed death receptor-1, sacituzumab govitecan, Trodelvy, TROPHY
Sacituzumab govitecan ໄດ້ຮັບການອະນຸມັດໄວຈາກ FDA ສໍາລັບມະເຮັງ urothelial ຂັ້ນສູງ
August 2021: Sacituzumab govitecan (Trodelvy, Immunomedics Inc.) was given accelerated approval by the Food and Drug Administration for patients with locally advanced or metastatic urothelial cancer (mUC) who had previously receiv..